|
Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. Metformin: from mechanisms of action to therapies. Cell Metab 20: 953-966, 2014. |
|
|
Gravel SP, Hulea L, Toban N, Birman E, Blouin MJ, Zakikhani M, Zhao Y, Topisirovic I, St-Pierre J, Pollak M. Serine deprivation enhances antineoplastic activity of biguanides. Cancer Res 74: 7521-33, 2014. |
|
|
Chapman JA, Pritchard KI, Goss PE, Ingle JN, Muss HB, Dent SF, Vandenberg TA, Findlay B, Gelmon KA, Wilson CF, Shepherd LE, Pollak MN. Competing risks of death in younger and older postmenopausal breast cancer patients. World J Clin Oncol 5: 1088-96, 2014. |
|
|
Paxton RJ, Jung SY, Vitolins MZ, Fenton J, Paskett E, Pollak M, Hays-Grudo J, Hursting SD, Chang S. Associations between time spent sitting and cancer-related biomarkers in postmenopausal women: an exploration of effect modifiers. Cancer Causes Control 25: 1427-37, 2014. |
|
|
DeCensi A, Puntoni M, Gandini S, Guerrieri-Gonzaga A, Johansson HA, Cazzaniga M, Pruneri G, Serrano D, Schwab M, Hofmann U, Mora S, Aristarco V, Macis D, Bassi F, Luini A, Lazzeroni M, Bonanni B, Pollak MN. Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial. Breast Cancer Res Treat 148: 81-90, 2014. |
|
|
Assayag J, Pollak MN, Azoulay L. Post-diagnostic use of beta-blockers and the risk of death in patients with prostate cancer. Eur J Cancer 50: 2838-45, 2014. |
|
|
Andrzejewski S, Gravel SP, Pollak M, St-Pierre J. Metformin directly acts on mitochondria to alter cellular bioenergetics. Cancer Metab. 2014 Aug 28. eCollection 2014. |
|
|
Mayers JR, Wu C, Clish CB, Kraft P, Torrence ME, Fiske BP, Yuan C, Bao Y, Townsend MK, Tworoger SS, Davidson SM, Papagiannakopoulos T, Yang A, Dayton TL, Ogino S, Stampfer MJ, Giovannucci EL, Qian ZR, Rubinson DA, Ma J, Sesso HD, Gaziano JM, Cochrane BB, Liu S, Wactawski-Wende J, Manson JE, Pollak MN, Kimmelman AC, Souza A, Pierce K, Wang TJ, Gerszten RE, Fuchs CS, Vander Heiden MG, Wolpin BM. Elevated circulating branched chain amino acids are an early event in pancreatic adenocarcinoma development. Nat Med 20: 1193-8, 2014. |
|
|
Bridges HR, Jones AJ, Pollak MN, Hirst J. Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. Biochem J 462: 475-87, 2014. |
|
|
Bensimon L, Yin H, Suissa S, Pollak MN, Azoulay L. The use of metformin in patients with prostate cancer and the risk of death. Cancer Epidemiol Biomarkers Prev 23: 2111-8, 2014. |
|
|
Laskov I, Drudi L, Beauchamp MC, Yasmeen A, Ferenczy A, Pollak M, Gotlieb WH. Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer. Gynecol Oncol 134: 607-14, 2014. |
|
|
Jacobs EJ, Newton CC, Silverman DT, Nogueira LM, Albanes D, Männistö S, Pollak M, Stolzenberg-Solomon RZ. Serum transforming growth factor-β1 and risk of pancreatic cancer in three prospective cohort studies. Cancer Causes Control 25:1083-91, 2014. |
|
|
Pollak M. Overcoming Drug Development Bottlenecks With Repurposing: Repurposing biguanides to target energy metabolism for cancer treatment. Nat Med 5: 591-593, 2014. |
|
|
Joshua AM, Zannella VE, Downes MR, Bowes B, Hersey K, Koritzinsky M, Schwab M, Hofmann U, Evans A, van der Kwast T, Trachtenberg J, Finelli A, Fleshner N, Sweet J, Pollak M. A pilot 'window of opportunity' neoadjuvant study of metformin in localised prostate cancer. Prostate Cancer Prostatic Dis 17: 252-8, 2014. |
|
|
Beasley JM, Wedick NM, Rajpathak SN, Xue X, Holmes MD, Gunter MJ, Wylie-Rosett J, Rohan TE, Pollak M, Kaplan RC, Hu FB, Sun Q, Strickler HD. Circulating IGF-axis protein levels and their relation with levels of plasma adipocytokines and macronutrient consumption in women. Growth Horm IGF Res 24: 142-9, 2014. |
|
|
Lai GY, Giovannucci EL, Pollak MN, Peskoe SB, Stampfer MJ, Willett WC, Platz EA. Association of C-peptide and leptin with prostate cancer incidence in the Health Professionals Follow-up Study. Cancer Causes Control 25: 625-32, 2014. |
|
|
Cao Y, Lindström S, Schumacher F, Stevens VL, Albanes D, Berndt SI, Boeing H, Bas Bueno-de-Mesquita H, Canzian F, Chamosa S, Chanock SJ, Diver WR, Gapstur SM, Gaziano JM, Giovannucci EL, Haiman CA, Henderson B, Johansson M, Marchand LL, Palli D, Rosner B, Siddiq A, Stampfer M, Stram DO, Tamimi R, Travis RC, Trichopoulos D, Willett WC, Yeager M, Kraft P, Hsing AW, Pollak M, Lin X, Ma J. Insulin-like Growth Factor Pathway Genetic Polymorphisms, Circulating IGF1 and IGFBP3, and Prostate Cancer Survival. J Natl Cancer Inst 106: 218, 2014. |
|
|
De Bono JS, Piulats JM, Pandha HS, Petrylak DP, Saad F, Antón-Aparicio LM, Sandhu SK, Fong P, Gillessen S, Hudes GR, Wang T, Scranton J, Pollak MN. Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res 20: 1925-34, 2014. |
|
|
Takeuchi A, Shiota M, Beraldi E, Thaper D, Takahara K, Ibuki N, Pollak M, Cox ME, Naito S, Gleave ME, Zoubeidi A. Insulin-like growth factor-I induces CLU expression through Twist1 to promote prostate cancer growth. Mol Cell Endocrinol 1: 117-125, 2014. |
|
|
Bramwell VH, Tuck AB, Chapman JA, Anborgh PH, Postenka CO, Al-Katib W, Shepherd LE, Han L, Wilson CF, Pritchard KI, Pollak MN, Chambers AF. Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial. Breast Cancer Res 16: 2014. |
|
|
Borugian MJ, Spinelli JJ, Gordon PB, Abanto Z, Brooks-Wilson A, Pollak MN, Warren LJ, Hislop TG, Gallagher RP. Fasting insulin and endogenous hormones in relation to premenopausal breast density (Canada). Cancer Causes Control 25: 385-94, 2014. |
|
|
Mireuta M, Birman E, Barmash M, Pollak M. Quantification of Binding of IGF-1 to BI 836845, a Candidate Therapeutic Antibody Against IGF-1 and IGF-2, and Effects of This Antibody on IGF-1:IGFBP-3 Complexes in Vitro and in Male C57BL/6 Mice. Endocrinology 155: 703-15, 2014. |
|
|
Rothermundt C, Hayoz S, Templeton AJ, Winterhalder R, Strebel RT, Bärtschi D, Pollak M, Lui L, Endt K, Schiess R, Rüschoff JH, Cathomas R, Gillessen S. Metformin in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Phase 2 Trial (SAKK 08/09). Eur Urol 66: 468-74, 2014. |
|
|
Bensimon L, Yin H, Suissa S, Pollak MN, Azoulay L. Type 2 diabetes and the risk of mortality among patients with prostate cancer. Cancer Causes Control 25: 329-38, 2014. |